Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (101-110 of 228) with videos related to

Pageof 23
Sort By:
European Radiology|September 22, 2016
Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancerLenka Minarikova, Wolfgang Bogner, Katja Pinker, et al.
Breast (Edinburgh, Scotland)|March 31, 2015
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisalFlora Zagouri, Paraskevi Liakou, Rupert Bartsch, et al.
Acta Neuropathologica|October 8, 2014
Predictive molecular markers in metastases to the central nervous system: recent advances and future avenuesAnna Sophie Berghoff, Rupert Bartsch, Adelheid Wöhrer, et al.
Breast Care (Basel, Switzerland)|April 21, 2025
Targeted Axillary Dissection Using Surgical Marker Navigation after Neoadjuvant Systemic Treatment in Breast Cancer Patients: A Single-Center ExperienceDaniel Egle, Christine Brunner, Magdalena Ritter, et al.
BMC Cancer|February 19, 2016
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trialChristiane Thallinger, Istvan Lang, Cvetka Grasic Kuhar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Gabriela Altorjai, et al.
Wiener Klinische Wochenschrift|January 27, 2006
Retrospective analysis of re-irradiation in malignant glioma: a single-center experienceRupert Bartsch, Hajo-Dirk Weitmann, Wolfgang Pennwieser, et al.
European Journal of Clinical Investigation|February 16, 2013
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancerTobias Arnold, Anna Michlmayr, Suzann Baumann, et al.
Neuro-Oncology|October 3, 2013
Invasion patterns in brain metastases of solid cancersAnna S Berghoff, Orsolya Rajky, Frank Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphomaMarkus Raderer, Stefan Wöhrer, Rupert Bartsch, et al.
Pageof 23

Showing results (101-110 of 228) with videos related to

Sort By:
Pageof 23
European Radiology|September 22, 2016
Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancerLenka Minarikova, Wolfgang Bogner, Katja Pinker, et al.
Breast (Edinburgh, Scotland)|March 31, 2015
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisalFlora Zagouri, Paraskevi Liakou, Rupert Bartsch, et al.
Acta Neuropathologica|October 8, 2014
Predictive molecular markers in metastases to the central nervous system: recent advances and future avenuesAnna Sophie Berghoff, Rupert Bartsch, Adelheid Wöhrer, et al.
Breast Care (Basel, Switzerland)|April 21, 2025
Targeted Axillary Dissection Using Surgical Marker Navigation after Neoadjuvant Systemic Treatment in Breast Cancer Patients: A Single-Center ExperienceDaniel Egle, Christine Brunner, Magdalena Ritter, et al.
BMC Cancer|February 19, 2016
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trialChristiane Thallinger, Istvan Lang, Cvetka Grasic Kuhar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Gabriela Altorjai, et al.
Wiener Klinische Wochenschrift|January 27, 2006
Retrospective analysis of re-irradiation in malignant glioma: a single-center experienceRupert Bartsch, Hajo-Dirk Weitmann, Wolfgang Pennwieser, et al.
European Journal of Clinical Investigation|February 16, 2013
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancerTobias Arnold, Anna Michlmayr, Suzann Baumann, et al.
Neuro-Oncology|October 3, 2013
Invasion patterns in brain metastases of solid cancersAnna S Berghoff, Orsolya Rajky, Frank Winkler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphomaMarkus Raderer, Stefan Wöhrer, Rupert Bartsch, et al.
Pageof 23